ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Decreased by First Trust Advisors LP

First Trust Advisors LP decreased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 13.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,210,441 shares of the biopharmaceutical company’s stock after selling 191,588 shares during the quarter. First Trust Advisors LP owned approximately 0.99% of ACADIA Pharmaceuticals worth $45,597,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Parametric Portfolio Associates LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 41.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 65,443 shares of the biopharmaceutical company’s stock valued at $2,250,000 after buying an additional 19,208 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 23.0% during the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 617 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Stifel Financial Corp now owns 8,708 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 260 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of ACADIA Pharmaceuticals by 2.2% during the first quarter. Teachers Advisors LLC now owns 125,022 shares of the biopharmaceutical company’s stock worth $4,298,000 after purchasing an additional 2,722 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 4.1% during the first quarter. TIAA CREF Investment Management LLC now owns 306,629 shares of the biopharmaceutical company’s stock worth $10,542,000 after purchasing an additional 12,096 shares in the last quarter. Institutional investors and hedge funds own 95.27% of the company’s stock.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.25% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/14/first-trust-advisors-lp-reduces-stake-in-acadia-pharmaceuticals-inc-acad.html.

Several research firms recently commented on ACAD. ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company reissued an “outperform” rating and issued a $46.00 price objective (up from $42.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $34.00 target price for the company in a report on Friday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $54.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $47.73.

Shares of ACADIA Pharmaceuticals Inc. (ACAD) traded down $0.56 on Monday, reaching $28.60. 1,805,900 shares of the company’s stock were exchanged, compared to its average volume of 1,674,653. ACADIA Pharmaceuticals Inc. has a 1 year low of $24.31 and a 1 year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. The firm had revenue of $35.58 million for the quarter, compared to analysts’ expectations of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The business’s revenue for the quarter was up 571.3% on a year-over-year basis. During the same period last year, the firm earned ($0.61) earnings per share. equities analysts expect that ACADIA Pharmaceuticals Inc. will post -2.44 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply